The company said revenue for Q3 2026 (three months ended September 30) rose to $3,810.0 million, up 6.9% from $3,563.5 million a year earlier, with diluted EPS at $3.22 and adjusted EPS at $4.78.

1. 01

   The company said revenue for Q3 2026 (three months ended September 30) rose to $3,810.0 million, up 6.9% from $3,563.5 million a year earlier, with diluted EPS at $3.22 and adjusted EPS at $4.78.

2. 02

   The company said operating cash flow for Q3 was $563.8 million, capital expenditures were $151.6 million, and free cash flow was $412.2 million. It said the increase in free cash flow was mainly driven by improvement in working capital, partially offset by planned increases in capital expenditures.

3. 03

   Labcorp updated its full-year enterprise revenue growth outlook to 5.9% to 6.7% and its adjusted EPS outlook to $18.30 to $18.70, from previous ranges of 5.4% to 6.3% and $18.10 to $18.55. The outlook assumes foreign exchange rates effective as of September 30, 2026.

4. 04

   The company said it invested $255.5 million in acquisitions and paid $58.2 million in dividends in Q3 2026. It said it has $1.4 billion remaining under its board-authorized share repurchase program.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.